Table 7.
Tacro C0 compliances within therapeutic ranges in patients with kidney alterations.
| Number of Subjects with IFTA | 1–5 Years (Tacro + MMF) |
>5 Years (Tacro + MMF) |
1–5 Years (Tacro) |
>5 Years (Tacro) |
Total | |
|---|---|---|---|---|---|---|
| 17 (23.6%) Out of 72 |
8 * (18.2%) Out of 44 |
3 (30.0%) Out of 10 |
6 (33.3%) Out of 18 |
34 (23.6%) Out of 144 |
||
| Therapeutic range | <3 µg/L | NA | - | NA | - | - |
| 3–5 µg/L | NA | 1 (12.5%) | NA | 1 (16.7%) | 2 (5.9%) | |
| >5 µg/L | NA | 7 (87.5%) | NA | 5 (83.3%) | 12 (35.3%) | |
| <4 µg/L | - | NA | - | NA | - | |
| 4–6 µg/L | 4 (23.5%) | NA | 1 (33.3%) | NA | 5 (14.7%) | |
| >6 µg/L | 13 (76.5%) | NA | 2 (66.7%) | NA | 15 (44.1%) |
IFTA—interstitial fibrosis and tubular atrophy; MMF—mycophenolate mofetil; Tacro—tacrolimus; NA—not applicable. * 1 of the subjects experienced an adverse drug reaction.